Table 1.
Baseline characteristics and prevalence of antimicrobial resistance of study patients
| VA-dual (n=168) |
VAC-triple (n=167) |
P value | |
| Age (years, mean±SD) | 61.2±11.5 | 61.3±10.4 | 0.912 |
| Range | 34–79 | 26–79 | |
| Sex (male/female) | 106/62 | 103/64 | 0.789 |
| BMI (kg/m2, mean±SD) | 23.9±3.2 | 23.9±3.4 | 0.979 |
| Range | 16.3–35.7 | 16.1–33.3 | |
| Disease-associated Helicobacter pylori | |||
| Gastric ulcer | 18 (10.7%) | 25 (15.0%) | 0.244 |
| Duodenal ulcer | 23 (13.7%) | 20 (12.0%) | 0.639 |
| ER for gastric neoplasia | 9 (5.4%) | 6 (3.6%) | 0.435 |
| MALT lymphoma | 1 (0.6%) | 0 (0%) | 0.318 |
| Cigarette smoking | 38 (22.6%) | 41 (24.6%) | 0.677 |
| Alcohol drinking | 25 (14.9%) | 29 (17.4%) | 0.536 |
| Daily use PPI before the trial | 10 (6.0%) | 6 (3.6%) | 0.311 |
| Antimicrobial resistance of H. pylori | |||
| Amoxicillin | 0 | 0 | – |
| Clarithromycin | 40 (23.8%) | 42 (25.1%) | 0.776 |
BMI, body mass index; ER, endoscopic resection; MALT lymphoma, mucosal-associated lymphoid tissue lymphoma; PPI, proton-pump inhibitor; VAC-triple, vonoprazan, amoxicillin and clarithromycin triple therapy; VA-dual, vonoprazan and amoxicillin dual therapy.